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OBJECTIVE — Despite increased information on the importance of an inappropriate inﬂam-
matory response in the acute Charcot process, there has been no previous attempt to deﬁne the
speciﬁc pathways that mediate its pathogenesis. Here, the role played by monocytes was
analyzed.
RESEARCH DESIGN AND METHODS — The immune phenotype of peripheral
monocytes was studied by ﬂuorescence-activated cell sorter analysis comparing patients with
acuteCharcot(n10)inboththeactiveandrecoveredphase,diabeticpatientswithneuropathy
(with or without osteomyelitis), and normal control subjects.
RESULTS — Whencomparedwithdiabeticcontrolsubjectsandhealthysubjects,monocytes
from acute Charcot patients showed a proinﬂammatory immune phenotype characterized by
increased production of proinﬂammatory cytokines, reduced secretion of anti-inﬂammatory
cytokines, increased expression of surface costimulatory molecules, and increased resistance to
serumwithdrawal-inducedapoptosis.Inaddition,thepatternofcirculatingcytokinesconﬁrmed
activation of proinﬂammatory cytokines. No modulation of the monocyte phenotype was doc-
umented in diabetic control subjects and healthy subjects, thus indicating that the proinﬂam-
matory alterations of monocytes are speciﬁc and causative of acute Charcot.
CONCLUSIONS — Together, these data provide evidence for the role of proinﬂammatory
changes in the immune phenotype of monocytes in the pathogenesis of acute Charcot. These
alterations may explain the abnormally intense and prolonged inﬂammatory response that char-
acterizes this disorder and may represent a potential therapeutic target for speciﬁc pharmaco-
logical interventions.
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D
iabetes is probably the most com-
mon cause of denervation-induced
destruction of joints (Charcot foot)
in the world today. Painlessness and ab-
normal foot biomechanics play an impor-
tant part in the pathogenesis of the
disorder. Recent attention, however, has
focused on several abnormalities, which
together suggest a more complex cause. A
pilot study by La Fontaine et al. (1) sug-
gests that abnormal calcitonin gene-
related peptide and endothelial nitric
oxide synthase activity may play a role in
the development of Charcot foot. Also,
receptoractivatorofthenuclearfactor-
ligand (RANKL)-activated peripheral
blood monocytes have been found to in-
duceasigniﬁcantincreaseinboneresorp-
tion in Charcot patients (2,3). Finally,
Jeffcoate, Game, and Cavanagh (4) drew
attention to the possible link between
proinﬂammatory cytokines and neuroar-
thropathyinthecontextofanexaggerated
inﬂammatoryresponsetotrauma.Thein-
ability of the Charcot patient to control
the intensity and the length of the local
inﬂammatory response would lead to in-
creased expression of tumor necrosis fac-
tor- (TNF-) and interleukin-1 (IL-1)
which, in turn, would trigger increased
expression of RANKL leading to matura-
tion of osteoclast and subsequent bone
changes (5–8). Despite increased infor-
mation on the importance of an inappro-
priate inﬂammatory response in the acute
Charcot process, there has been no previ-
ous attempt to deﬁne the speciﬁc path-
ways that mediate its pathogenesis. Here,
the role played by monocytes was ana-
lyzed. The immune phenotype of mono-
cyteswasassessedbytestingspontaneous
and induced production of proinﬂamma-
tory and anti-inﬂammatory cytokines by
measuring the expression of surface mol-
ecules (CD40, CD80, and CD86), which
enable monocytes to became competent
costimulatory cells and to activate T-
lymphocytes responses (9–11), and by
studying the ability of monocytes to un-
dergo apoptosis, an important homeo-
static mechanism that contributes to
regulate the intensity and length of the
inﬂammatory response (12). Patients
withacuteCharcot,inboththeactiveand
recovered phase, were compared with di-
abetic patients with neuropathy (with or
without osteomyelitis) and normal con-
trol subjects.
RESEARCH DESIGN AND
METHODS— We studied 10 consec-
utive diabetic patients (4 with type 1 dia-
betes and 6 with type 2 diabetes) without
macrovascular complications referred to
the University of Rome’s diabetic foot
clinicforunexplainedandrelativelypain-
less increased swelling of a foot and ankle
absent of active foot ulceration and/or
signs of soft tissue infection, with no his-
tory of recent (within 6 months) immu-
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corticosteroids and anti–TNF- com-
pounds, fever, evidence of infectious dis-
eases, inﬂammatory disorders, or any
kind of malignancy, and presenting the
magnetic resonance diagnostic character-
istics of stress injuries: swelling, local
warmth,andclinicalinstabilityduetolig-
amentous injury/occult trauma (at this
stage, radiographic changes are absent or
minimal, but the typical bone marrow
edema is present at magnetic resonance
imaging); (8 age- and sex-matched dia-
betic patients with polyneuropathy with-
out macrovascular complications and
clinical and radiological evidence of a
history of Charcot foot; 8 age- and sex-
matched diabetic patients with polyneu-
ropathy and clinical and radiological
documented foot osteomyelitis without
clinicalandradiologicalevidenceofahis-
tory of Charcot foot; and 8 age- and sex-
matchedhealthysubjects).Bloodsamples
by peripheral venipuncture from Charcot
patientswereﬁrstobtainedwithin24hof
meeting enrollment criteria and then just
after recovery (as determined by clinical
and magnetic resonance imaging evalua-
tions). The blood was immediately sepa-
rated from plasma by centrifugation,
storedat4°C,andprocessedwithin1h.
Serum was obtained for circulating cyto-
kine determination and immediately
stored at 80°C. A single blood sample
was obtained from diabetic control and
healthy control subjects. This study was
approved by the ethics committee of the
University of Rome “Policlinico Tor Ver-
gata” hospital. Informed consent was ob-
tained from all subjects.
Compounds
Lipopolysaccharide (LPS) from Esche-
richia coli 0111/B4 was purchased from
Sigma Chemical (St. Louis, MO). Recom-
binant granulocyte-macrophage colony–
stimulating factor was obtained from
Sandoz Research Institute (East Hanover,
NJ) and contained 5.4 10
6 chronic my-
elogenous leukemia units per mg of
glycoprotein.
Limulus amebocyte lysate test
Allthecompoundsandmediausedinthis
study were analyzed for endotoxin con-
tamination by the limulus amebocyte
lysate test (QCL-1000; BioWhittaker,
Walkersville, MD). All the samples ana-
lyzed were found free of endotoxin con-
tamination (0.1 EU/ml).
Antibodies
For ﬂuorescence-activated cell sorter
(FACS) analysis, the following monoclo-
nal antibodies were used: anti-CD40,
anti-CD80, anti-CD86, anti–TNF-, an-
ti–IL-1, anti–IL-6, anti–IL-4, and anti–
IL-10 (PharMingen, San Diego, CA).
Staining was performed with ﬂuorescein
isothiocyanate–, phycoethrin-, and
Quantum Red–conjugated antibodies.
ELISA immunoassay
The analyses of TNF-, IL-1, IL-6, IL-4,
and IL-10 were done with commercially
available ELISA test kits (R&D Systems,
Minneapolis,MN).Accordingtotheman-
ufacturer’s speciﬁcations, these ELISAs
arespeciﬁcfortherelativeinterleukin.All
thesamplesweredeterminedinduplicate
in a single analytical set. Intra-series vari-
ation coefﬁcient was 20%.
Cell stimulation
Peripheral blood from control subjects or
patients was enriched for peripheral
blood mononuclear cells (PBMNCs) by
centrifugation over Ficoll Hypaque. The
cells were cultured in RPMI-1640 me-
Figure 1—Spontaneous cytokine production by monocytes from acute Charcot case subjects and
controlsubjects.Spontaneous(A)andinducible(monocytesstimulatedfor18hby100ng/mlLPS)
(B) cytokine production was assessed by FACS, as intracellular accumulation on a single-cell
basis. Appropriate controls with isotype-matched irrelevant mAbs were carried out and consis-
tently showed 1% of positive cells. For each analysis, 10
4 monocytes were gated according to
scatter characteristics designed to include only viable cells. Fluorescence data were expressed as
percentage of positive cells after subtraction of background isotype-matched values. The data
represent the means 	 SD (error bars). *P  0.05, with respect to control subjects. **P 
 0.005,
with respect to diabetic control and healthy subjects.
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inactivated FCS, 2 mmol/l L-glutamine,
50 units/ml penicillin, and 50 g/ml
streptomycin,referredtoascompleteme-
dium. The cells were kept at 37°C in a
humidiﬁed atmosphere of 5% CO2 in air,
in 96-well V-bottom plates (Corning,
Corning, NY) at a concentration of 5 
10
5 cells/well/250 l. For the determina-
tion of intracellular cytokine production
by FACS, PBMNCs from patients and
control subjects were cultured at a con-
centrationof510
5cells/well/250lfor
18 h in 96-well V-bottom plates (Corn-
ing) in complete medium in the presence
orintheabsenceof100ng/mlLPS.Thirty
minutes after stimulation, 1 g/ml of the
protein transport inhibitor brefeldin A
(Sigma Chemical) was added. At the end
of the incubation period, the cells were
analyzed by FACS for intracellular cyto-
kine production.
Surface marker and intracellular
cytokine staining
After incubation, the cells were washed
and stained for surface markers. Then,
cells were either analyzed by FACS to de-
termine cell surface antigen expression or
suspended in Cytoﬁx/Cytoperm solution
(Pharmingen), stained for intracellular
cytokines, and then analyzed by FACS.
FACS
Flow cytometry was performed using a
FACScan ﬂow cytometer and analyzed
with Cell Quest software (Becton Dickin-
son). For each analysis, 10
4 monocytes
were gated according to scatter character-
isticsdesignedtoincludeonlyviablecells.
Assessment of hypodiploid DNA
formation
Hypodiploid DNA formation (a reliable
markerofapoptosis)wasassessedbypro-
pidium iodide assay as previously de-
scribed (13). In brief, PBMNCs (5  10
5)
were incubated in RPMI-1640 alone for
72 h. At the end of the incubation period,
the cells were resuspended in 1.5-ml
propidium iodide solution containing
250-g DNase-free RNase A. The pro-
pidium iodide ﬂuorescence of individual
nuclei was measured by FACS.
Statistics
Thenormalityofvariabledistributionwas
assessed by the Kolmogorov-Smirnov
goodness-of-ﬁttest.Comparisonbetween
distribution of two variables for a single
group was performed by either the Stu-
dent paired t test or Mann-Whitney U
test, as appropriate. All P values are two-
tailed. P values 0.05 were considered
signiﬁcant. Statistical analyses were per-
formed using SPSS version 10.0 (SPSS,
Chicago, IL) statistical package.
RESULTS
Patients
The mean age was similar between pa-
tients with acute Charcot (6 male and 4
female subjects) and diabetic control pa-
tients with (5 male and 3 female subjects)
or without (6 male and 2 female subjects)
oteomyelitis (53 	 2.8 vs. 59 	 2.9 and
59 	 7 years, P  0.05), as was the mean
age between the former and healthy con-
trol participants (4 male subjects and 4
female subjects) (53 	 2.8 vs. 47 	 2.7
years, P 
 0.05). The mean duration of
diabetes in acute Charcot case subjects
and diabetic control subjects with or
without oseomyelitis was 31 	 5.1, 27 	
4.6, and 36 	 2.9 years, respectively. All
diabetic patients, both acute Charcot case
subjects and control subjects, were on in-
sulin therapy. The mean A1C was 7.4 	
1% in acute Charcot case subjects and
7.1 	 0.5% and 7.6 	 2.2% in diabetic
controlsubjectswithorwithoutosteomy-
elitis, respectively.
Increased proinﬂammatory and
reduced anti-inﬂammatory cytokine
production by monocytes from acute
Charcot patients
Blood monocytes from case and control
subjects were evaluated for spontaneous
(Fig. 1A) and inducible (Fig. 1B) TNF-,
IL-1, IL-6, IL-4, and IL-10 production.
AsshownbyFACSanalysisforintracellu-
lar cytokine production, monocytes from
diabetic control and healthy control sub-
jects did not spontaneously produce de-
tectable amounts of TNF-, IL-1, IL-6,
IL-4,andIL-10.Asopposed,alimitedbut
detectable production of TNF-, IL-1,
and IL-6, but not IL-4 and IL-10, was ob-
served in cells from patients with acute
Charcot. When activated by LPS, mono-
cytes from patients with acute Charcot
produced signiﬁcantly more TNF-, IL-
1,andIL-6,butlessIL-4andIL-10,than
monocytes from diabetic control and
healthy control subjects. Interestingly,
both spontaneous and inducible cytokine
production by monocytes from acute
Charcot case subjects signiﬁcantly de-
creased after recovery from the acute
phase.
Circulating cytokines in patients
with acute Charcot
Circulating cytokines in acute Charcot
case subjects were analyzed during the
acutephaseoftheprocessandafterrecov-
ery. As shown in Table 1, the concentra-
tions of TNF-, IL-1, and IL-6 were
slightlybutsigniﬁcantlyhigherthanthose
found in control subjects and decreased
after recovery to values similar to those
found in control subjects.
Upmodulation of surface molecules
in monocytes from Charcot patients
As shown in Fig. 2, diabetic control and
healthy control subjects did not statisti-
cally differ with respect to CD40, CD80,
and CD86 expression (P 
 0.05). In con-
trast, monocytes from acute Charcot pa-
tients showed a statistically signiﬁcant
increase of both percentage of positive
cells and intensity of expression of these
moleculeswithrespecttodiabeticcontrol
and healthy control subjects. CD40,
CD80, and CD86 expression markedly
decreased in patients with acute Charcot
after recovery, reaching values that were
Table 1—Circulating cytokines in acute Charcot cases
Cytokine
Cytokine concentrations in sera (pg/ml)
Acute Charcot Diabetic control subjects
Onset Recovered
With
osteomyelitis
Without
osteomyelitis
Healthy
subjects
TNF- 5.2 	 3.2* 1.5 	 0.9 2.8 	 2.3 2.1 	 1 2.6 	 1.2
IL-1 0.6 	 0.3* 0.125 0.125 0.125 0.125
IL-6 15.3 	 7.4* 7.4 	 4.2 3 	 2.9 5.2 	 2.7 6.7 	 3.5
IL-4 0.25 0.25 0.25 0.25 0.25
IL-10 0.78 0.78 0.78 0.78 0.78
Dataaremeans	SD.TNF-andIL-6weredetectablein100%ofthesamples;IL-1wasdetectablein3out
of 9 acute Charcot patients at the onset time point. The lowest standards were as follows: TNF-, 0.5 pg/ml;
IL-1, 0.125 pg/ml; IL-6, 0.156 pg/ml; IL-4, 0.25 pg/ml; IL-10, 0.78 pg/ml. *P  0.05, with respect to
control subjects.
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beticcontrolandhealthycontrolsubjects.
Increased resistance of monocytes
from acute Charcot case subjects to
serum withdrawal-induced
apoptosis
As shown in Fig. 3A, just after separation,
1% of monocytes were nonviable as de-
termined by Trypan blue assay, and no
hypodiploid DNA was detectable in case
and control subjects. The percentage of
hypodiploid DNA increased over time in
cultured cells in both case and control
subjects. After 72 h of culture, the per-
centage of hypodiploid DNA was signiﬁ-
cantly lower in cells from acute Charcot
case subjects as compared with cells from
diabetic and healthy control subjects. Ti-
trationexperiments(Fig.3B)showedthat
the addition of LPS at concentrations 1
pg/ml reduced hypodiploid DNA forma-
tion by 
30% in monocytes from acute
Charcot patients but had a very limited
effectincellsfromrecoveredCharcotcase
subjects and control subjects. Moreover,

99% and 50% reduction of hypodip-
loid DNA formation could be obtained
with 10 pg/ml LPS in monocytes from
acute Charcot patients and recovered
Charcot case subjects and control sub-
jects, respectively.
CONCLUSIONS — We show here
that in patients with acute Charcot, pe-
ripheral monocytes acquire a proinﬂam-
matory immune phenotype characterized
by increased production of proinﬂamma-
tory cytokines, reduced secretion of anti-
inﬂammatory cytokines, increased
expression of costimulatory surface mol-
ecules, and increased resistance to
apoptosis.
Monocytes play a pivotal role in the
development and maintenance of the in-
ﬂammatory response. These cells are
the major source of proinﬂammatory
(TNF-, IL-1, and IL-6) as well as anti-
inﬂammatory cytokines (IL-4 and IL-10)
(14–16). Alterations in the correct tim-
ing, intensity, and balance of expression
of proinﬂammatory versus anti-
inﬂammatory cytokines by monocytes re-
sult in pathologic modulation of the
inﬂammatory response. Thus, the activa-
tion of inﬂammatory and suppression of
anti-inﬂammatory cytokines that we have
found in patients with acute Charcot is
consistent with the abnormally intense
and prolonged inﬂammatory response
that characterizes the acute phase of this
disease. A growing body of evidence is
now supporting the possibility that this
inﬂammatory response plays a pivotal
pathogenetic role in the changes in bone
and joints that develop in this disorder
(4). Indeed, TNF- and IL-1, released
during the inﬂammatory process, trigger
increased expression of RANKL (5,6).
ThisleadstoactivationofNF-Bandmat-
uration of osteoclasts (7,8). The effect of
IL-6 on bone formation/resorption is
more controversial. Indeed, several re-
ports support the possibility that IL-6
could in fact induce an osteocytic pheno-
type (17). As opposed, there is evidence
that IL-6 can stimulate osteoclasts differ-
entiation and bone resorption by an indi-
rect mechanism, increasing interactions
between osteoblasts and osteoclasts (18).
At variance with Devaraj et al. (19) and
Kulseng et al. (20), who reported in-
creased proinﬂammatory cytokine pro-
duction by monocytes from diabetic
patients, with respect to healthy subjects
we did not ﬁnd differences between dia-
betic control and healthy subjects. It is
possible that these seemingly conﬂicting
Figure 2—Upmodulation of surface molecules in monocyte-macrophages from Charcot patients.
The expression of CD40, CD80, and CD86 was analyzed by FACS on CD14 gated cells in fresh
explanted PBMCs. Appropriate controls with isotype-matched irrelevant mAbs were carried out
and consistently showed 1% of positive cells. For each analysis, 10
4 monocytes were gated
according to scatter characteristics designed to include only viable cells. Fluorescence data were
expressed as mean channel ﬂuorescence (A) and as percentage of positive cells (B) after subtrac-
tion of background isotype-matched values. The data represent the means 	 SD (error bars). *P
 0.05, with respect to control subjects; **P 
 0.05, with respect to diabetic control and healthy
subjects.
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experimental procedures used to detect
cytokine production in cultured mono-
cytes. Both Devaraj et al. and Kulseng et
al. measured cytokine production by
ELISA testing of supernatants from un-
fractionated cell cultures. Here we used a
FACS-based technique that allowed us to
identify producer cells by cell surface
markers and cytokine production simul-
taneously (13). It is likely that this tech-
niqueismoresuitabletostudyaprimarily
cell-basedphenomenonthansimplemea-
surement of cytokine production by a
bulk-release method such as ELISA test-
ing of supernatants from unfractionated
cell cultures.
CD40, CD80, and CD86 are involved
in antigen presentation to T-cells, CD4
T-cell activation (e.g., cytokine expres-
sion), and proliferation/differentiation
(9–11). Thus, the enhanced expression
of these molecules on Charcot-derived
monocytes suggests that increased co-
stimulatory signals were received by T-
cells, which might alter the balance
between regulation and inﬂammation
and further increased bone loss. Indeed,
activated T-cells are able to produce
RANKL and initiate the differentiation
program that leads to the formation of
mature osteoclasts (21).
Unless activated, monocytes undergo
apoptosis. Proinﬂammatory cytokines,
such as IL-1 or TNF-, protect mono-
cytes from apoptosis (22). This suggests
that monocytes recruited to a site of in-
ﬂammation receive stimuli allowing for
survival through activation. Inversely,
when inﬂammation abates, the rate of
monocyte apoptosis increases markedly.
Thus, apoptosis represents an important
homeostatic mechanism that regulates
the duration and intensity of inﬂamma-
tion (23). As we show here, monocytes
from patients with acute Charcot were
signiﬁcantly more resistant to apoptosis
than monocytes from control subjects.
Nonetheless,wecannotexcludethatcon-
taminating lymphocytes contributed to
the measured apoptosis in the monocyte
cultures. However, because lymphocytes
survive for weeks, a major contribution
fromthiscelltypeisunlikely(22,23).Itis
possible that this increased resistance to
apoptosis, which may be related to the
increased release of IL-1 and TNF-,
may contribute, at least in part, to the in-
ability of Charcot patients to terminate
the inﬂammation in the affected limb.
The proinﬂammatory alterations we
have found in the phenotype of mono-
cytes from acute Charcot patients appear
to be speciﬁc to this condition. Indeed,
both the phenotype of monocytes from
diabetic patients with uncomplicated
neuropathy and that of monocytes from
diabetic patients with neuropathy and
osteomyelitis-associated foot inﬂamma-
tion was not different from that of cells
from healthy control subjects. This indi-
cates that neither diabetes nor neuropa-
thy or inﬂammation, per se, is associated
with any modulation of the inﬂammatory
response of monocytes. Interestingly, we
found that all the modiﬁcation of the im-
mune phenotype of monocytes disap-
peared after recovery in patients with
acute Charcot. This suggests that the ini-
tiating cause that triggers the inﬂamma-
tory response in patients with acute
Charcot acts in an environment where
mechanisms that physiologically control
the intensity and duration of inﬂamma-
tion are lacking. Calcitonin gene-related
peptide (CGRP), a 37-amino acid peptide
widely distributed in the central and pe-
ripheral nervous systems and mainly in
sensory nerves (24), has been shown to
inhibit proinﬂammatory cytokine pro-
duction and augment the release of IL-10
by monocytes (25). Thus, local reduction
of CGRP in the denervated Charcot foot
may affect the activation of monocytes
with increased production of proinﬂam-
Figure 3—Kinetics of hypodiploid DNA formation in monocyte-macrophages. PBMCs were cul-
tured in medium with no added serum and hypodiploid DNA formation was determined at indi-
cated intervals (A). PBMCs were cultured in medium with no added serum with different LPS
concentrations,andhypodiploidDNAformationwasdeterminedat72h(B).Theredﬂuorescence
due to propidium iodide staining of the DNA was registered on a logarithmic scale at 
620 nm.
Theforwardandsidescatterofparticlesweresimultaneouslymeasured.Celldebriswasexcluded
from analysis by appropriately raising the forward scatter threshold. The residual cell debris had
a very low DNA ﬂuorescence emission and a low side scatter signal. At least 10
4 cells of each
sample were analyzed. *P  0.05, with respect to recovered acute case subjects and control
subjects.
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anti-inﬂammatory cytokines.
In conclusion, these data provide ev-
idence for a pathogenetic role of proin-
ﬂammatory changes in the immune
phenotype of monocyte in acute Charcot.
These alterations may explain the abnor-
mally intense and prolonged inﬂamma-
tory response that characterizes this
disorder and may represent a potential
therapeutic target for speciﬁc pharmaco-
logical interventions.
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